Please login to the form below

Oesophageal cancer

This page shows the latest Oesophageal cancer news and features for those working in and with pharma, biotech and healthcare.

Opdivo improves survival in oesophageal cancer

in oesophageal cancer from its phase 3 CHECKMATE-648 study. ... The US regulator will review the combination treatment for the first-line treatment of patients with advanced or metastatic gastric cancer, gastro-oesophageal junction cancer or oesophageal

Latest news

Keytruda plus chemotherapy gains US approval for advanced oesophageal cancer

Merck &Co’s – known as MSD outside the US and Canada – Keytruda has received an approval from the US Food and Drug Administration (FDA) for the treatment of advanced oesophageal cancer. . ... status. “There have been few advances in improving
BMS aims for US approval of Opdivo combo in stomach cancer

The US regulator will review the combo treatment for the first-line treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction cancer (GEJC) or oesophageal adenocarcinoma (EAC). ... free survival (PFS) in patients with
Roche’s tiragolumab plus Tecentriq combo wins FDA breakthrough therapy designation

such as stage III NSCLC and locally advanced oesophageal cancer. ... On top of these studies, tiragolumab is being evaluated in metastatic oesophageal squamous cancer and cervical cancer.
BMS’ Opdivo wins EU approval for second-line oesophageal cancer

The US Food and Drug Administration (FDA) has already approved Opdivo for second-line advanced oesophageal cancer treatment, giving the immunotherapy a green light in June. ... Opdivo’s main rival in the oesophageal cancer setting is Merck &Co’s (MSD)
Keytruda plus chemotherapy cuts risk of death by 27% in advanced oesophageal cancer

Merck &Co/MSD’s checkpoint inhibitor Keytruda cut the risk of disease progression or death by 35% in patients with locally advanced or metastatic oesophageal and gastroesophageal junction (GEJ) cancer. ... Merck’s main rival in oesophageal cancer is

More from news
Approximately 7 fully matching, plus 17 partially matching documents found.

Latest Intelligence

20 for 2020 – Five pharma companies to watch

The company’s biggest play last year was licensing Daiichi Sankyo’s cancer candidate trastuzumab deruxtecan for an eyewatering. ... Other important read-outs in first-line kidney, oesophageal and gastric cancer are also due this year, as well as
Chinese biotech’s global ambitions

has just achieved a landmark approval in China for its own ‘home-grown’ cancer medicine. ... Tislelizumab is in global phase III trials in a number of tumour types, including non-small cell lung cancer, hepatocellular carcinoma and oesophageal
Deal Watch March 2016

Acquisition of royalty rights. $1, 140. Blueprint Medicines/ Roche. Small molecules targeting kinases for cancer immunotherapy. ... Collaboration – marketing &distribution. $171. AVEO Oncology/ CANbridge Life Sciences. AV-203; ErbB3 (HER3) inhibitory

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

Senior Account / Programme Manager - MedComms - Buckinghamshire: Highly Competitive Remuneration packages

Editor & Senior Editor - Medical Communications - Home Based: Highly Competitive Salary, Bonus &Benefits

Medical Writer, Senior Medical Writer, Principal Medical Writer,...: Highly Competitive Salary, Bonus &Benefits

FREELANCE Medical Writer, Senior Medical Writer, Principal Medic...: Highly Competitive Day Rate, Bonus &Benefits

Freelance Medical Writer - Creative Healthcare Comms - 2 month t...: Excellent Day Rate

Client Services Director – London or Home Based – Medical Commun...: Highly Competitive Salary, Bonus &Benefits

Senior Content Editor - Biotechnology: Salary TBC

Senior Account Director & Associate Director - Healthcare Ad...: Highly Competitive Salary, Bonus &Benefits

Home Working Medical Copy Writer & Senior Medical Copy Write...: Highly Competitive Salary, Bonus &Benefits

Account Management: Competitive Salary Offered

Freelance Account Manager - Creative Healthcare Comms - Immediat...: Excellent Day Rate

Senior Leadership Role – Medical Communications – North West: Highly Competitive Salary, Bonus &Benefits

PMHub

Add my company

JPA Health

JPA Health is an award-winning public relations, marketing and advocacy firm known for sharing our clients’ commitment to making people...

Latest intelligence

InSite Events™ National Pharma Meeting: A Customer Story: How our client leveraged Impetus Digital’s white-glove service, 360° coverage and care, and award-winning InSite Events™ platform to successfully transfer their annual national meeting online....
Fear or encouragement, which is best to drive behaviour change?: The communications industry depends on fear of the perceived loss of something, in order to create the hope found in a product benefit. But, if if left too long unchecked,...
The unheard, unseen, and uncorrected effects of COVID-19: The disproportionate effects of the pandemic have been highlighted amongst ethnic minorities, so is it likely that ethnic minorities will be more worried about participating? And could this exacerbate inequalities...